Filter your results
- 3
- 1
- 4
- 4
- 1
- 2
- 1
- 4
- 3
- 3
- 1
- 1
- 1
- 1
- 4
- 4
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PAJournal of Cellular Physiology, 2018, 233 (10), pp.6814-6824. ⟨10.1002/jcp.26547⟩
Journal articles
inserm-02402031v1
|
||
Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistanceAnti-Cancer Drugs, 2018, 29 (8), pp.748-755. ⟨10.1097/CAD.0000000000000647⟩
Journal articles
inserm-02402025v1
|
|||
|
HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.Molecular Cancer, 2010, 9 (1), pp.79. ⟨10.1186/1476-4598-9-79⟩
Journal articles
inserm-00668221v1
|
||
|
Celastrol Reverses Palmitic Acid-Induced Insulin Resistance in HepG2 Cells via Restoring the miR-223 and GLUT4 PathwayCanadian Journal of Diabetes, 2019, 43 (3), pp.165-172. ⟨10.1016/j.jcjd.2018.07.002⟩
Journal articles
inserm-02402019v1
|